HP-1901

N/A

Report date: 2025/01/26 19:14:24

Base Information

Drug NameHP-1901
Drug Alias Nameanti-IL-17A/F nanobody (Shenzhen Huapu Drug Development)HP-1901
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-17F inhibitorsInterleukin 17A inhibitors
TargetsInterleukin-17FInterleukin 17A
Therapy Area/IndicationsPsoriasisDermatitis, AtopicArthritis, Rheumatoid +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShenzhen Huapu Drug Research and Development Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Huapu Drug Research and Development Co LtdPregene (Shenzhen) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisDermatitis, AtopicArthritis, Rheumatoid +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A